German Protein Therapeutic company retains Aagami for its India strategic Partnership

Published : 15 Sep 2011


Today a German company with novel class of protein therapeutics has retained Aagami consulting services for seeking partnership for Licensing and Co-development with Indian Biotechs.

A technology invented by Munich Technology university has been in development by this Munich area company.The new class of molecules called Anticalin are recombinantly engineered lipocalins and represent a next generation therapeutic human protein class proprietary to the company.

Their lead molecule is targeting VEGF for the treatment of solid tumors, has been tested in a phase 1 open-label, dose escalating trial and is found to be safe and well tolerated.  Out of its database of several hundred companies, Aagami has identified over 3 dozen companies which are good potential for such partnership. We feel pretty confident to have this Emerging Market strategic alliance come to fruition.

 


×
Twitter